The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.88BCNY
576.11M · vs all stocks (USD)
Updated Aug 19, 2026
Revenue (TTM)
654.72MCNY
97.24M · vs all stocks (USD)
Updated Aug 19, 2026
Profit Margin
-1.54%
vs Diagnostics & Research peers
Updated Aug 19, 2026
52-Week Change
-8.12%
vs all stocks
Updated Aug 19, 2026
Market Capitalization
3.88BCNY
576.11M · vs all stocks (USD)
Updated Aug 19, 2026
Enterprise Value
3.07BCNY
455.22M · vs all stocks (USD)
Updated Aug 19, 2026
Forward P/E
22.78x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Price to Sales (TTM)
6.07x
vs Diagnostics & Research peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 5.92×.Updated Aug 19, 2026
Price to Book (MRQ)
1.04x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Enterprise to Revenue
4.68x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Enterprise to EBITDA
43.55x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 61.12×.Updated Aug 19, 2026
Gross Margin
43.66%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Profit Margin
-1.54%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Operating Margin
-4.63%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Return on Assets (TTM)
-1.21%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Return on Equity (TTM)
-0.53%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Revenue (TTM)
654.72MCNY
97.24M · vs all stocks (USD)
Updated Aug 19, 2026
Revenue per Share (TTM)
1.03CNYUpdated Aug 19, 2026
Quarterly Revenue Growth
-3.70%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Gross Profit (TTM)
287.99MCNY
42.77M · vs all stocks (USD)
Updated Aug 19, 2026
EBITDA (TTM)
50.15MCNY
7.45M · vs all stocks (USD)
Updated Aug 19, 2026
Net Income (TTM)
-10.09MCNY
-1.50M · vs all stocks (USD)
Updated Aug 19, 2026
Quarterly Earnings Growth (YoY)
-38.70%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Operating Cash Flow (TTM)
356.92MCNY
53.01M · vs all stocks (USD)
Updated Aug 19, 2026
Levered Free Cash Flow (TTM)
186.49MCNY
27.70M · vs all stocks (USD)
Updated Aug 19, 2026
5-Year Average Dividend Yield
1.70%
vs all stocks
Updated Aug 19, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Minority Interest (Equity)
-86.54MCNYFY2025 · Dec 31, 2025
Revenue
669.64MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
365.19MCNYFY2025 · Dec 31, 2025
Gross Profit
304.45MCNYFY2025 · Dec 31, 2025
Operating Income
-136.39MCNY
-20.26M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-169.32MCNYFY2025 · Dec 31, 2025
Income Tax Expense
12.96MCNYFY2025 · Dec 31, 2025
Net Income
-182.28MCNYFY2025 · Dec 31, 2025
EBIT
-166.14MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
50.15MCNYFY2025 · Dec 31, 2025
Research & Development
62.39MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
172.91MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
11.75MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
18.41MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
3.18MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.2100CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.2100CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
623.54MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
623.54MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-182.28MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
51.34MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
185.38MCNYFY2025 · Dec 31, 2025
Free Cash Flow
94.62MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
707.97MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-182.28MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
21.01MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
337.93MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
8.72MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-90.76MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-761.24MCNYFY2025 · Dec 31, 2025
Sale of Investments
747.59MCNYFY2025 · Dec 31, 2025
Other Investing Activity
-38.84MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-143.25MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
46.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-45.06MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-3.50MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-139.17MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-141.73MCNYFY2025 · Dec 31, 2025
Shares Outstanding
646.50MSharesUpdated Aug 19, 2026
Float Shares
368.83MSharesUpdated Aug 19, 2026
% Held by Insiders
44.42%
vs all stocks
Updated Aug 19, 2026
% Held by Institutions
2.03%
vs all stocks
Updated Aug 19, 2026
Total Cash (MRQ)
881.71MCNY
130.95M · vs all stocks (USD)
Updated Aug 19, 2026
Total Cash per Share (MRQ)
1.38CNYUpdated Aug 19, 2026
Total Debt (MRQ)
86.17MCNY
12.80M · vs all stocks (USD)
Updated Aug 19, 2026
Total Debt to Equity (MRQ)
0.0231x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Current Ratio (MRQ)
5.39x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Book Value per Share (MRQ)
5.94CNYUpdated Aug 19, 2026
Total Assets
4.15BCNY
616.01M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.89BCNYFY2025 · Dec 31, 2025
Total Liabilities
485.86MCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.25BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
133.53MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
352.33MCNYFY2025 · Dec 31, 2025
Cash
797.20MCNYFY2025 · Dec 31, 2025
Cash Equivalents
1.36MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
798.56MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
240.15MCNYFY2025 · Dec 31, 2025
Accounts Receivable
696.97MCNYFY2025 · Dec 31, 2025
Inventory
61.86MCNYFY2025 · Dec 31, 2025
Accounts Payable
86.36MCNYFY2025 · Dec 31, 2025
Short-term Debt
13.09MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
1.12MCNYFY2025 · Dec 31, 2025
Long-term Debt
76.48MCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
2.25MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
646.50MCNYFY2025 · Dec 31, 2025
Retained Earnings
2.33BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
3.66BCNY
543.85M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
110.15MCNYFY2025 · Dec 31, 2025
52-Week Low
4.75CNYUpdated Aug 19, 2026
52-Week High
10.07CNYUpdated Aug 19, 2026
52-Week Change
-8.12%
vs all stocks
Updated Aug 19, 2026
50-Day MA
5.41CNYUpdated Aug 19, 2026
200-Day MA
6.07CNYUpdated Aug 19, 2026
Avg 10-Day Volume
22.22MSharesUpdated Aug 19, 2026
Avg 30-Day Volume
20.44MSharesUpdated Aug 19, 2026
Diluted EPS (TTM)
-0.1700CNYUpdated Aug 19, 2026
3 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable